专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008102937A1 MESENCHYMAL STEM CELL-MEDIATED AUTOLOGOUS DENDRITIC CELLS WITH INCREASED IMMUNOSUPPRESSION 审中-公开
标题翻译：间质干细胞介导的自体免疫细胞增殖免疫抑制
公开(公告)号：WO2008102937A1
公开(公告)日：2008-08-28
申请号：PCT/KR2007/003681
申请日：2007-07-31
申请人： CREAGENE INC. , LIM, Dae Seog , JEONG, Ju Ah , KANG, Mi-Sun , LEE, Hyun Soo , BAE, Yong Soo
发明人： LIM, Dae Seog , JEONG, Ju Ah , KANG, Mi-Sun , LEE, Hyun Soo , BAE, Yong Soo
IPC分类号： C12N5/06 , C12N5/08 , C12N5/00 , A61P37/02
CPC分类号： C12N5/064 , A61K2035/122 , C12N2502/1358
摘要： The present invention relates to a method for preparing dendritic cells which have an enhanced potential to suppress immune responses, dendritic cells carrying a potential to suppress immune responses, and a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses. The present dendritic cells having an enhanced potential to suppress immune responses can be utilized for treating various diseases or disorders through the suppression of immune responses. In addition, the enhanced immunotolerance potential of the dendritic cells of this invention ensures the cells to be effectively used as an immunosuppressive agent.
摘要翻译：本发明涉及一种制备树突细胞的方法，该方法具有增强的抑制免疫应答的潜力，具有抑制免疫应答潜力的树突状细胞，以及包含能诱导免疫抑制反应的树突状细胞的药物组合物。具有增强的抑制免疫应答潜力的本发明的树突状细胞可用于通过抑制免疫应答来治疗各种疾病或病症。此外，本发明的树突细胞的增强的免疫耐受潜力确保细胞被有效地用作免疫抑制剂。

2. 发明申请

WO2007129858A1 NOVEL USE OF MLN51 GENE AND PROTEIN 审中-公开
标题翻译：新的使用MLN51基因和蛋白质
公开(公告)号：WO2007129858A1
公开(公告)日：2007-11-15
申请号：PCT/KR2007/002259
申请日：2007-05-08
申请人： CREAGENE INC. , JANG, Jin Ah , LIM, Dae Seog , LEE, Hyun Soo , BAE, Yong Soo
发明人： JANG, Jin Ah , LIM, Dae Seog , LEE, Hyun Soo , BAE, Yong Soo
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.
摘要翻译：本发明涉及MLN 51基因或蛋白质的新用途。 MLN 51基因和蛋白质与类风湿性关节炎的发展密切相关，作为类风湿性关节炎，特别是慢性滑膜炎的生物标志物和治疗靶点。

3. 发明申请

WO2006126864A1 ANIMAL MODELS CARRYING TUMORS EXPRESSING HUMAN PROSTATE CANCER-SPECIFIC ANTIGEN AND METHOD FOR ANALYZING PREVENTION AND TREATMENT EFFICACY OF DENDRITIC CELLS-DERIVED IMMUNOTHERAPEUTICS USING THE ABOVE 审中-公开
标题翻译：携带肿瘤的动物模型表达人前列腺癌特异性抗原和分析预防和治疗使用上述细胞衍生的免疫球蛋白的治疗效果的方法
公开(公告)号：WO2006126864A1
公开(公告)日：2006-11-30
申请号：PCT/KR2006/002028
申请日：2006-05-27
申请人： CREAGENE INC , LEE, Dong Sung , LEE, Woo Bok , JEON, Choon Ju , BAE, Yong Soo
发明人： LEE, Dong Sung , LEE, Woo Bok , JEON, Choon Ju , BAE, Yong Soo
IPC分类号： A01K67/027
CPC分类号： A01K67/0271 , A01K2227/105 , A01K2267/0331
摘要： The present invention relates to a method for analyzing the prevention and treatment efficacy of a dendritic cell- derived immunotherapeutic for prostate cancer using an animal model carrying tumors expressing a human prostate cancer- specific antigen, which comprises the steps of : (a) (a') administering to a normal animal other than human dendritic cells to be analyzed, or (a") administering to a normal animal other than human a cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the normal animal; (b) (b' ) administering to the animal the cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the animal when the step (a' ) is performed in the step (a) , or (b") administering to the animal with cancer dendritic cells to be analyzed when the step (a") is performed in the step (a) ; and (c) determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for prostate cancer by measuring the formation or growth of cancer cells originated from the cancer cell line in the animal.
摘要翻译：本发明涉及使用携带表达人前列腺癌特异性抗原的肿瘤的动物模型分析树突状细胞衍生的前列腺癌免疫治疗剂的预防和治疗功效的方法，其包括以下步骤：（a）（a）对于待分析的人树突细胞以外的正常动物施用，或（a）向表达人前列腺癌特异性抗原的癌细胞系的除人之外的正常动物施用以在正常动物中诱导癌症的（a“） b）（b'）在步骤（a'）或（b“）中施用步骤（a'）或（b”）时向动物施用表达人前列腺癌特异性抗原的癌细胞系以在动物中诱导癌症在步骤（a“）中在步骤（a）中进行分析的具有癌症树突状细胞的动物;和（c）通过测定来确定树突状细胞作为前列腺癌的免疫治疗剂的预防和治疗功效环绕来自动物的癌细胞系的癌细胞的形成或生长。

4. 发明申请

WO2006126865A1 METHOD FOR MEASURING EFFECTIVELY THE ACTIVITY OF CYTOTOXIC T LYMPHOCYTE IN HUMAN AND OUT-BRED ANIMALS 审中-公开
标题翻译：用于有效测定人和动物的细胞毒性T淋巴细胞活性的方法
公开(公告)号：WO2006126865A1
公开(公告)日：2006-11-30
申请号：PCT/KR2006/002029
申请日：2006-05-25
申请人： CREAGENE INC , JUNG, Sang Won , JEON, Choon Ju , BAE, Yong Soo
发明人： JUNG, Sang Won , JEON, Choon Ju , BAE, Yong Soo
IPC分类号： C12Q1/68
CPC分类号： G01N33/5091 , C07K7/06
摘要： The present invention relates to a method for measuring the activity of cytotoxic T lymphocytes (CTLs) , which comprises the steps of: (a) preparing peripheral blood mononuclear cells (PBMCs) from blood of an animal; (b) preparing mature dendritic cells by isolating monocytes from the PBMCs, differentiating the monocytes into dendritic cells for presenting an antigen molecule and pulsing dendritic cells with the antigen molecule to obtain the mature dendritic cells; (c) preparing the CTLs as an effector cell by stimulating the PBMCs with the mature dendritic cells to activate and amplify the CTLs; (d) preparing target cells by pulsing the PBMCs, monocytes or B cells with a cytoplasmic transduction peptide (CTP) -antigen complex generated by linking the antigen molecule of step (b) to the CTP; (e) treating the target cells with the effector cells; and (f) analyzing the lysis of the target cells. In addition, the present invention relates to a kit for measuring the activity of cytotoxic T lymphocytes.
摘要翻译：本发明涉及一种测定细胞毒性T淋巴细胞活性的方法，包括以下步骤：（a）从动物血液制备外周血单核细胞（PBMC）; （b）通过从PBMC分离单核细胞来制备成熟树突状细胞，将单核细胞分化成树突状细胞以呈递抗原分子并用抗原分子脉冲树突状细胞以获得成熟树突状细胞; （c）通过用成熟树突状细胞刺激PBMC来激活和扩增CTL来制备CTL作为效应细胞; （d）通过将步骤（b）的抗原分子与CTP连接而产生的细胞质转导肽（CTP） - 抗原复合体脉冲地培养PBMC，单核细胞或B细胞来制备靶细胞; （e）用效应细胞处理靶细胞; 和（f）分析靶细胞的裂解。此外，本发明涉及一种测定细胞毒性T淋巴细胞活性的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式